The CCAAT/Enhancer-binding protein β (C/EBPβ) was first identified as a regulator of differentiation and inflammatory processes in adipose tissue and liver. Although C/EBPβ was initially implicated in synaptic plasticity, its function in the brain remains largely unknown. We have previously shown that C/EBPβ regulates the expression of genes involved in inflammatory processes and brain injury. Here, we have demonstrated that the expression of C/EBPβ is notably increased in the hippocampus in a murine model of excitotoxicity. Mice lacking C/EBPβ showed a reduced inflammatory response after kainic acid injection and exhibited a dramatic reduction in pyramidal cell loss in the CA1 and CA3 subfields of the hippocampus. These data reveal an essential function for C/EBPβ in the pathways leading to excitotoxicity-mediated damage and suggest that inhibitors of this transcription factor should be evaluated as possible neuroprotective therapeutic agents.
Introduction
4 the immune response, and morphogenesis (Poli, 1998; Ramji and Foka, 2002) .
Recently, it has been shown that C/EBPβ mRNA is expressed in the central nervous system of adult mice (Nadeau et al., 2005; Sterneck and Johnson, 1998) , as well as in mouse cortical astrocytes and in hippocampal neurons in vitro (Cardinaux and Magistretti, 1996; Yano et al., 1996; Yukawa et al., 1998) . Several studies, including those from our laboratory, have suggested that this protein may have important functions in the brain. It has been shown that C/EBPβ plays an important role in the consolidation of long-term memory, suggesting a very important role for this protein in the hippocampus (Alberini et al., 1994; Taubenfeld et al., 2001) , and Menard et al have defined a MEK-C/EBP pathway as being essential for the differentiation of cortical progenitor cells into postmitotic neurons (Menard et al., 2002) . We have demonstrated that C/EBPβ serves as a critical factor in neuronal differentiation (Cortes-Canteli et al., 2002) . In addition, using microarray analysis in neuronal cells overexpressing C/EBPβ, we have found that this protein induces the expression of several genes involved in inflammatory processes and brain injury (Cortes-Canteli et al., 2004) .
Given the limited understanding of C/EBPβ involvement in brain injury and our prior speculation that this transcription factor may play a role in this process, we sought to address the function of C/EBPβ in cells of the central nervous system in response to a brain insult in vitro and in vivo. Our results reveal an strong induction of C/EBPβ in the hippocampus of wild type mice following KA injection. Notably, there was a pronounced reduction in glial activation and neuronal damage in C/EBPβ knockout mice. These data point to a key role for C/EBPβ in excitotoxic brain injury.
Results

C/EBPβ induction in glial primary cultures from C/EBPβ
+/+ mice. We have previously demonstrated that cell lines stably transfected with C/EBPβ exhibited an increase in the expression of many genes involved in inflammation and brain injury (Cortes-Canteli et al., 2004) . In addition, we have shown that when these cells were subjected to injury using an in vitro "scratch-wound" model, the expression of C/EBPβ was also up-regulated. These observations have prompted us to investigate whether the expression of the endogenous C/EBPβ gene in primary cultures of glia could be regulated after neural injury. In order to address this question we first investigated the expression of C/EBPβ in glial cultures from C/EBPβ +/+ mice, in response to different agents known to cause neural damage through different mechanisms. The C/EBPβ signal in these experiments was significantly induced by lipopolysaccharide (LPS), the kinase inhibitor staurosporine, KA and glutamate. As shown in Fig. 1A , C/EBPβ basal expression levels, measured by Western blot analysis, were low, both in microglial and astrocyte primary cultures prepared from wild type mice. However, an increase in C/EBPβ was detected after treatment of microglial cells with either LPS or KA (2.3-and 1.5-fold, respectively, compared to non-treated cultures). Addition of LPS or staurosporine to astrocytes also potently induced C/EBPβ expression (4.2-and 2.2-fold, respectively, compared to non-treated cultures), and a lower increase was observed with KA (1.7-fold) or glutamate (1.3-fold). At the subcellular level (see confocal images shown in Fig. 1B ,C) the increase in C/EBPβ protein expression was localized to the nucleus in both microglia and astrocytes. KA and glutamate-treated astrocyte cultures (Fig. 1B ) also showed an increase in C/EBPβ protein in the nucleus, although the induction was lower than the one observed following LPS or staurosporine treatment.
No C/EBPβ signal was detected in astrocytes and microglial cultures from C/EBPβ -/-6 mice after LPS treatment, confirming the specificity of the antibody used (Fig. 1D,E) . A similar increase in C/EBPβ levels was also observed in rat primary cultures after treatment with LPS or staurosporine (see Supplementary Fig. S1 ).
Less pro-inflammatory protein induction in C/EBPβ -/-primary microglial cultures. To further evaluate the possible role of C/EBPβ in the inflammatory response in neural tissues, we next performed in vitro experiments with primary cultures of glial cells from C/EBPβ knockout and wild type mice. We tested the capacity of C/EBPβ -deficient microglial cells to express genes involved in the inflammatory response after stimulation with LPS and KA. The Western blots displayed in Fig. 2A show that, in contrast to control cells, C/EBPβ-deficient microglia failed to induce the expression of Interleukin-1β (IL-1β) in response to LPS and KA. The expression levels of the proinflammatory enzyme cyclooxygenase type-2 (COX-2) were also slightly reduced in protein lysates from C/EBPβ -/-microglial cultures. These data were further confirmed by confocal analysis. As shown in Fig. 2 , the number of microglial cells expressing IL-1β ( Fig. 2B ) or COX-2 ( Fig. 2C ) was reduced in cultures established from C/EBPβ-deficient animals. Quantification of both western blot and immunocytochemistry analysis revealed that IL-1β expression was significantly reduced (~50%) in C/EBPβ-deficient microglial cultures after treatment with both LPS and KA. A decrease in COX-2 levels (~15%) was also observed, although in this case the reduction was not statistically significant. Together, these data suggested that C/EBPβ helps to modulate the induction of proinflammatory mediators in microglial cells.
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To ascertain a possible colocalization of IL-1β and COX-2 with C/EBPβ, a multiple labeling approach was performed. As depicted by Fig. 2B and C, both IL-1β and COX-2 colocalized with C/EBPβ in the majority of microglial cells established from wild type animals. These data provide evidence that the up-regulation of the gene encoding C/EBPβ triggered by LPS or KA takes place essentially within the same cells where induction of pro-inflammatory agents is observed.
The expression level of C/EBPβ protein increases in the hippocampus with excitotoxic injury. We next investigated the in vivo role of C/EBPβ in a wellestablished model of excitotoxic brain injury. Adult mice received intrahippocampal injections of either vehicle or KA and, at different times post-injection, the animals were perfused and brain tissue was prepared for immunohistochemical analyses. These studies revealed that the injection of KA noticeably increased the expression of C/EBPβ on the ipsilateral side of the hippocampus of wild type mice when compared to vehicleinjected controls at 24 hours and 72 hours after surgery (Fig. 3A) . Activation was noted mainly in the dentate gyrus and, as anticipated, was completely absent in C/EBPβ-deficient mice (Fig. 3C ), a finding that underscores the utility of the A16 antibody for the in vivo immunohistochemical studies. In the KA-injected animals occasional C/EBPβ-positive cells were also detected within the CA1 and CA3 subfields (data not shown), and in the stratum radiatum. In order to identify the cell type-specificity of C/EBPβ activation, we next performed a double-labeling analysis using Neurotrace, anti-glial fibrillary acidic protein (GFAP), and tomato lectin to identify neurons, astrocytes, and microglia, respectively. C/EBPβ immunoreactivity was detected in the nuclei of granule neurons of the dentate gyrus as well as in glial cells 24 h after KA injection (Fig. 3B) (Screpanti et al., 1995) .
Impaired pro-inflammatory protein induction in C/EBPβ-deficient mice. We also evaluated the production of the cytokine IL-1β, which is secreted by glia in response to KA administration and known to enhance neuronal death. IL-1β was elevated in the hippocampus of C/EBPβ +/+ mice 72 hours after injection (Fig. 5A ), although a slight increase was also detected at 24 hours (data not shown). In the C/EBPβ -/-mice, no upregulation of IL-1β was observed, consistent with a lack of glial activation. These results are in agreement with those obtained in primary cultures of C/EBPβ -/-microglial cells ( Fig. 2A ,B) where a reduced induction of IL-1β in response to LPS and KA treatment was observed. The IL-1β + cells also express the astroglial marker GFAP in both the hilus and the molecular layers of the dentate gyrus (Fig. 5B) . We also found a small number of cells that expressed IL-1β and also bound to the tomato lectin ( Fig.   5B ). We did not identify any cells that coexpressed IL-1β and the neuronal marker
Neurotrace.
In addition, we also studied the accumulation of the inducible COX-2 enzyme.
Overexpression of COX-2 in neural cells appears central to many neuroinflammatory conditions. As shown in Fig. 5C , the protein levels of COX-2 were clearly increased in the hippocampus at both 24 and 72 hours following KA injection of C/EBPβ
animals, relative to vehicle-injected controls (not shown). COX-2 staining was mainly observed in the granule cells of the dentate gyrus, although some scattered cells were also detected in the stratum radiatum. A small increase in COX-2 levels was also observed in some of the KA-treated C/EBPβ -/-animals (mainly at 24 hours), but not as robustly or as persistently as that seen in the C/EBPβ +/+ mice. Using a double-labeling analysis we found that all COX-2-positive cells in wild-type animals were indeed neurons ( Fig. 5D ). In these cells, the intracellular distribution of the immunoreactivity was predominantly perinuclear, which is consistent with the known subcellular localization of this enzyme (Nogawa et al., 1997) . COX-2 did not appear to colocalize with the microglial marker tomato lectin or with the astrocytic marker GFAP (data not shown).
Next, we analyzed the expression of 24p3/LCN2 and histidine decarboxylase, two genes up-regulated by C/EBPβ (Cortes-Canteli et al., 2004) and probably implicated in inflammation and brain injury. Fig. 6 shows that the protein levels of both 24p3 and histidine decarboxylase were increase 24 hours after treatment with KA and that this increase, as previously observed for IL-1β and COX-2, was markedly reduced in the hippocampus of C/EBPβ -/-animals.
C/EBPβ-deficient mice are resistant to excitotoxin-mediated neuronal degeneration. In order to better understand the role of C/EBPβ in vivo, we examined the sensitivity of mice lacking C/EBPβ to KA-induced neurodegeneration. To determine whether C/EBPβ expression was associated with CA1 and CA3 pyramidal cell death after excitotoxicity, hippocampal sections were stained with Fluoro-Jade B (Schmued et al., 1997) Fig 7D) .
Discussion
In the present study we have shown that mice lacking C/EBPβ are less susceptible to glial activation and neuronal damage following KA exposure. These results clearly establish C/EBPβ as a factor required for the development of excitotoxic brain injury.
Excitotoxic brain damage is considered one of the major mechanisms by which neurons die in the adult central nervous system and it contributes to the pathogenesis of many central nervous system disorders, including neurodegenerative disease, brain ischemia, epilepsy, and trauma (Coyle and Puttfarcken, 1993; Guo et al., 1999; Hossmann, 1994; Lynch and Dawson, 1994) . Therefore, our results suggest that C/EBPβ should be considered as a possible therapeutic target in brain injury and neurodegenerative disorders where excitotoxic neuronal cell death and inflammation processes are involved.
The first clues suggesting a possible role for C/EBPβ in brain injury stemmed from in vitro studies showing increased activity of this transcription factor during the induction of inflammation and damage in neural cells. The expression of C/EBPβ has been previously shown to be induced by pro-inflammatory cytokines in primary cultures of murine astrocytes (Cardinaux et al., 2000) and by mechanical injury in neuroblastoma cells (Cortes-Canteli et al., 2004) . In addition, we have demonstrated that overexpression of C/EBPβ induces terminal differentiation and cell death in neuroblastoma N2A cells (Cortes-Canteli et al., 2002) and also up-regulates the expression of genes previously suggested to be involved in brain injury and inflammatory processes (Cortes-Canteli et al., 2004) . The in vitro studies presented here show that LPS, staurosporine, KA and glutamate are each capable of increasing the 13 expression of C/EBPβ in primary cultures of murine glial cells. These findings are consistent with previous studies indicating that C/EBPβ is induced in primary cultures of glial cells under inflammatory conditions (Cardinaux et al., 2000; Chen et al., 2004; Jana et al., 2005) or after glutamate treatment (Yano et al., 1996) . Importantly, we have shown here that the activation of IL-1β is markedly reduced in glial cultures from C/EBPβ -/-mice, suggesting that the expression of this gene could be regulated by C/EBPβ. In this context, C/EBPβ has been previously shown to regulate expression of inflammatory mediators and pro-inflammatory cytokines, including IL-1β and COX-2, in different tissues Yang et al., 2000) , and C/EBPβ response elements have been described in the IL-1β and COX-2 genes (Wadleigh et al., 2000; Yang et al., 2000) .
Excitotoxicity proceeds through a complex signaling pathway that includes the participation of numerous signaling molecules. The identification of the genes that are activated or repressed in specific responses to brain injury, and understanding how such alterations in gene expression affect survival and neuronal function, is a central issue in the treatment of neurodegenerative diseases. We have demonstrated that the in vivo intrahippocampal injection of KA resulted in a strong induction of C/EBPβ, which was detected in the nuclei of granule neurons of the dentate gyrus as well as in a subset of hippocampal astrocytes and microglia. These observations are consistent with previous findings showing that C/EBPβ mRNA is expressed in neurons throughout the mature brain, with high levels in the hippocampus (Sterneck and Johnson, 1998) . The observed induction is also consistent with previous studies showing that the expression of C/EBPβ mRNA is increased in facial motor neurons following axonal injury (Nadeau et al., 2005) . There is considerable evidence that KA treatment is associated with a 14 significant activation of astrocytes and microglial cells and the increased expression of classic pro-inflammatory agents, likely through direct regulation by C/EBPβ (Wadleigh et al., 2000; Yang et al., 2000) . This hypothesis is supported by our data showing that the morphological changes associated with the activation of astrocytes and microglial cells, as well as the induction of IL-1β and COX-2, are markedly reduced in C/EBPβ null mice following KA injection.
The regulation of pro-inflammatory mediators is generally considered a key mechanism in neuronal cell death. The enzyme, COX-2, is involved in the pathogenesis of multiple neurological disorders associated with inflammation (Giovannini et al., 2003; Teismann et al., 2003) and local increases in COX-2 expression in vivo have been associated with inflammation, seizures and ischemia (Nogawa et al., 1997; Strauss et al., 2000) . In addition, an increase in IL-1β expression has been observed in several types of brain injury including excitotoxicity (Rothwell and Luheshi, 2000) , where it has been shown that exogenous IL-1β enhances chemically induced seizures in rats (Vezzani et al., 2002) . IL-1β has also been implicated in a number of neurodegenerative conditions and is generally believed to have neurotoxic actions (Rothwell and Luheshi, 2000) .
Therefore the suppression of both COX-2 and IL-1β expression in neurons and glial cells, respectively, in response to tissue injury in C/EBPβ -/-mice may be directly responsible for the observed reduction in hippocampal neuronal loss. Consistent with this idea, it has been previously shown that the promoter of both genes is directly regulated by C/EBPβ Shirakawa et al., 1993; Sirois and Richards, 1993; Wadleigh et al., 2000; Wu et al., 2005; Yang et al., 2000; Zhang and Rom, 1993) .
The C/EBPβ-deficient animals in this study displayed a dramatic reduction in neuronal degeneration in the CA1 and CA3 subfields of the hippocampus (Fig. 7) , as well as a less marked disruption of these hippocampal neuronal fields 24 and 72 hours postinjection. In this regard, it has been previously suggested that C/EBPβ may be involved in several models of neurodegenerative disease (Bonin et al., 2004; Colangelo et al., 2002; Giri et al., 2002; Obrietan and Hoyt, 2004) . Taken (Logdberg and Wester, 2000) , and it is also involved in brain damage. Prior reports have shown that lipocalin 24p3 is up-regulated after ischemia (Anwaar et al., 1998; MacManus et al., 2004) and it has been implicated in the apoptosis that follows an inflammatory response (Devireddy et al., 2001) . Since this gene is mainly expressed in the granular layer of the dentate gyrus (Fig. 6A) , the same place where the induction in C/EBPβ takes place, it is tempting to speculate that this gene could also be a mediator of the effects of C/EBPβ after an excitotoxic insult. The other gene analyzed, histidine decarboxylase, converts L-histidine in the neurotransmitter histamine and its expression has been linked to brain inflammation processes (Musio et al., 2006) . Increased histidine decarboxylase activity has been found in the hypothalamus after intracerebroventricular administration of LPS (Niimi et al., 1993) . Interestingly, histamine has been implicated in the pathogenesis of Parkinson Disease, contributing to the loss of dopaminergic neurons in 6-hydroxydopamine-lesioned rats (Liu et al., 2007) , and increased histamine innervation has been described in the substantia nigra of Parkinson Disease patients (Anichtchik et al., 2000) . Another gene that we found to be up-regulated by C/EBPβ in our microarray analysis was ornithine decarboxilase (Cortes-Canteli et al., 2004) , an enzyme that plays a key role in the polyamine biosynthetic pathway. Intriguingly, it has been shown that the inhibition of polyamine synthesis abolished neurodegeneration (Soulet and Rivest, 2003) and that increased polyamine metabolism is neurotoxic (Porcella et al., 1991).
These observations collectively suggest that one of the mechanisms by which the loss of C/EBPβ in the CNS leads to the attenuation of neuronal injury after excitotoxic damage is by inhibiting the induction of C/EBPβ-dependent proinflammatory genes. In this regard, Kapadia et al, using a model of transient cerebral ischemia, have recently provided evidence for the up-regulation of many of the genes previously identified in our studies (Cortes-Canteli et al., 2004) , including ornithine decarboxylase and 24p3 (Kapadia et al., 2006) .
In summary, our findings have suggested that C/EBPβ plays a critical role in the processes leading to the glial activation and resulting neuronal damage that occurs in response to an excitotoxic insult. Accordingly, this transcription factor merits serious consideration as a potential therapeutic target for the treatment of brain disorders. For the COX-2 double-immunofluorescence, the protocol was similar to the one described above with some modifications. Briefly, the floating sections were blocked in PBS containing 0.25% Triton X-100 and 3% normal goat serum and incubated overnight with COX-2 polyclonal antibody (Cayman). Then, Alexa secondary antibody was added for 1 hour at RT together with Neurotrace Fluorescent Nissl stain (Molecular Probes). Finally, the tissue was mounted with Vectashield (Vector Labs) mounting medium with DAPI (Vector Labs) to counterstain nuclei, and the sections were 21 examined as described for immunocytochemistry. The sequential mode was used to acquire fluorescence images to avoid any interference from overlapping fluorescence. Fluoro-Jade staining. To evaluate neuronal degeneration, Fluoro-Jade B staining was used (Schmued et al., 1997) . Briefly, the sections were mounted on gelatin-coated slides and then let them dried at RT. After that, the slides were immersed in 100% alcohol, followed by 70% alcohol and distilled water. Then the slides were incubated shaking gently for 15 minutes in 0.06% potassium permanganate solution followed by 30 minutes in dark in the staining solution (0.001% Fluoro-Jade B dye, Chemicon). After staining, the sections were rinsed in distilled water, let them dry, immersed in xylene and mounted with DePeX (Serva). Images were analyzed by confocal microscope, as 
Materials and Methods
Mice. C/EBPβ
